Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential?

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best stocks under $5 with highest upside potential. Autolus Therapeutics plc (NASDAQ:AUTL) received a Buy rating from Needham analyst Gil Blum on October 27, who set a $10 price target on the stock and based the optimistic outlook on the company’s promising clinical data.

The rating update came the same day Autolus Therapeutics plc (NASDAQ:AUTL) presented clinical data updates at the American College of Rheumatology Convergence 2025, reporting that “data from Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS, with 50 million cell dose selected for Phase 2 pivotal study.”

The company also reported that the preliminary efficacy data exhibited attainment of the definition of remission in SLE (DORIS) in 83% of patients, along with complete renal response (CRR) in 50% of patients. It added that all remissions and responses are ongoing with no “evidence of disease activity at a median follow-up of 8.9 months.”

Autolus Therapeutics plc (NASDAQ:AUTL) is on track to dose the first patient in the Phase 2 trial in lupus nephritis (LN) by the end of the year. Management reported that Dr. Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, stated:

“Data from the CARLYSLE study shows that obe-cel has the potential to make a meaningful clinical impact in patients with severe refractory SLE who are currently without approved treatment options. We observe durable responses in up to 12 months of follow-up and an encouraging safety profile in this difficult to treat patient population. All patients were able to reduce glucocorticosteroids to physiological levels, and responses, including kidney responses, occur early and are durable.”

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, and focuses on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies.

While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.